BDBM311971 US10166214, Example 107::US10675268, Example 107::US9789082, Example 107

SMILES Cc1cccc2c(nn(C)c12)C(C)(C)NC(=O)[C@@H]1[C@H]2CNC[C@@H]12

InChI Key InChIKey=ZWNVABDSAWDSPA-WDNDVIMCSA-N

Data  15 KI  2 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 17 hits for monomerid = 311971   

TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi:  3.40nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi:  3.40nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi:  3.40nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi:  4.30E+3nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi:  4.30E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 1(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi:  4.30E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 3(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi: >8.60E+3nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 3(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi: >8.60E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 3(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi: >8.60E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi: >9.60E+3nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi: >9.60E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 2(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi: >9.60E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 5(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi: >9.85E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 5(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi: >9.85E+3nMAssay Description:Receptor binding assays refer to a technique in which labeled receptor ligands are used to detect binding to a receptor. In competition experiments t...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 5(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataKi: >9.85E+3nMAssay Description:For the binding experiments 200 μL of membrane homogenate from one of the following protein amounts is used: hSSTR1 (40 μg/well); hSSTR2 (2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataEC50:  0.200nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSomatostatin receptor type 4(Homo sapiens (Human))
Centrexion Therapeutics

US Patent
LigandPNGBDBM311971(US10166214, Example 107 | US10675268, Example 107 ...)
Affinity DataEC50:  0.200nMAssay Description:The activation of the SSTR4 receptor (Gi coupled) causes an inhibition of intracellular cAMP after stimulation with Forskolin, which can be quantifia...More data for this Ligand-Target Pair
In DepthDetails US Patent